We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Medgenics | LSE:MEDU | London | Ordinary Share | COM SHS USD0.0001 (DI) |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 392.50 | 0.00 | 01:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 392.50 | GBX |
Medgenics (MEDU) Share Charts1 Year Medgenics Chart |
|
1 Month Medgenics Chart |
Intraday Medgenics Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 17/4/2014 | 07:46 | MEDGENICS - THE NEXT GENENTECH? | 529 |
| 06/7/2011 | 14:51 | MEDGENICS - UNKNOWN SHARE WITH TECHNOLOGY WORKING AND MULTIPLE DEAL DISCUSSIONS | 359 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 27/3/2014 08:40 by fanboy1 Kalinit/CountSVS transferred mine from MEDG to MEDU free of charge. However I made the request after having held for a year (which was apparantly a condition) and back in October. It actually took until around mid February for them to appear in my online account as MEDU. I just rang up and asked. |
Posted at 27/3/2014 06:09 by kalinit Hi Count ChrisI have some with Self trade - they are forcing me to sell as they no longer settle on CREST. SIPP centre will transer it to the MDGN ticker without charge. TDW will also allow me to transfer MEDU to them and they will transer to MDGN but there may be a charge. Not sure what other peoples brokers are doing - anyone else can help Count Chris. It is really poor timing doing it just before what we hope are good results and the new trial. |
Posted at 26/3/2014 09:40 by 237gmoney Does anyone know how it will work with the share transfer. The price in the US is now circ. £4.75 yet the buy price in the UK is around £4.35.With the transfer costs (if there is any) exchange rate differences there will not be much difference in the end but all depends on the transfer price when it comes. I no longer hold any here but watch daily. |
Posted at 03/3/2014 12:02 by 237gmoney Also why publish the RNS on MEDG but not on MEDU? very odd. Once again two fingers up to all small shareholders. very poor if you ask me. |
Posted at 13/2/2014 12:40 by 237gmoney Thanks, I do look in from time to time at IMM. Interesting company. Will keep watching it for now.I currently hold stock in a Bangladesh pharma - Beximco Pharma - Ticker in London BXP.L. The share price is materially below the Stock price equivalent in Dhaka at the moment. Hopefully that will correct itself soon as that is a growing company and a few new investors have moved in there over the last few months. For Medgenics I found the Institutional holders have expanded in recent months as well - Vanguard, Belmont, B Gifford and Bridgeway are all buying stock. No wonder the stock is rising in the US if this continues. L&G have increased their holding by over 200k shares since yr end. |
Posted at 13/2/2014 09:26 by 237gmoney SK, Agreed. US Biotech companies are always valued higher than say if it were a UK company and the management behind Medgenics do have quite a record at building successful Pharma companies so there is expectation here that this will work. When the US trials start, the momentum will start to build and the share price will react imo similar to the last two spikes. I think the move in the last few weeks is the start of that. However, just because the trials will start does not mean this is a slam dunk. Far from it. In fact, even if the trails are a success the company will probably need to carry out more fundraising to get production of the next generation biopump off the ground. But you would have to say this would be much easier with the team in place and there will be many more companies willing to put their hands in their pockets, including Baxters. Its going to be an interesting few weeks/months here what ever way you look at it. |
Posted at 16/12/2013 08:37 by 237gmoney I see the shares in US took a bit of a knock Friday so today the share price over here just following suit.The delay in annoucing the US Trials was disappointing here. I understand there was a change in management and the new team need time to reassess the situation but it seems this has held up progress. Will look to buy more of these next year if it goes any lower here but for the next couple of months not expecting anything of note here. The new Management team might have a good track record but just not sure where they plan on taking the company now so will wait for things to settle. |
Posted at 06/8/2013 15:00 by 237gmoney Overall Q2 results in line with expectations and nice to see the company still have $30m cash in the bank.This company should be fully funded right through 2014 now and also they plan no go into partnership agreements with third parties for the the biopumps and also the US clinical trials. Hopefully news of the US trails is not too far away which should lift the share price. I see in the MD&A the company hired a consultant in June for 24 months at a cost of 100k shares. The company also employed other consultants earlier on in the year and were also given shares as payment. It is therefore in their best interests that the share price rises from here on in. |
Posted at 26/3/2013 13:08 by 237gmoney News out. The Underwriters have exercised their option to purchase the extra 840k shares and 420k warrants which is good news. This gives Medgenics an extra $2.27m and underscores the confidence in the company and the Projects that are being undertaken.This should boost the share price considering the options were at $5.25 a share with the current share price under $5 in the US. Hopefully the company can now come out with some encouraging CKD results to bring some life back to the share price as we move into the summer months. With interim results from the clinical trials due mid 2013 their should be a bit excitment about the company heading towards the latter part of the year. |
Posted at 17/6/2011 07:03 by sicilian_kan Note that the current MEDU share price is worth $2.73, but the US AMEX share price is now at $3.40 / share. The MEDU shares are therefore 25% undervalued compared to their US stock. Makes and excellent buying opportunity as on any takeover, all shares are sold at the same price and this will be relative to the US price. |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
